The U.S. Department of Health and Human Services awarded Tempus AI a $60 million contract under ARPA‑H to provide testing and contract research services for a project that uses biomarkers to develop adaptive cancer treatment strategies. Tempus will support biomarker identification and testing workflows that aim to enable adaptive therapeutic approaches across tumor types; ARPA‑H funding underscores federal interest in rapid, data‑driven clinical research to personalize oncology care. The contract expands Tempus’s role as a clinical‑data and sequencing services provider and could accelerate integration of multiomic biomarker signals into adaptive trial designs and clinical decision support tools.